Gene-Tailored drug dosing aims to protect young transplant patients
NCT ID NCT06529536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a child's genetic information to guide the dose of the anti-rejection drug tacrolimus can help achieve safer and more effective drug levels after a solid organ transplant. About 45 children aged 1-18 who receive a kidney, liver, or heart transplant will take part. The goal is to reduce side effects from too much or too little medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID ORGAN TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Children's Hospital
RECRUITINGMelbourne, Victoria, 3052, Australia
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••